Sun Sep 15 13:45:00 UTC 2024: ## Replimune’s Oncolytic Immunotherapy Shows Promise in Melanoma Patients

**WOBURN, Mass. (GLOBE NEWSWIRE)** – Replimune Group, Inc. (NASDAQ: REPL) announced today that its lead product candidate, RP1, in combination with nivolumab, demonstrated clinically meaningful and durable anti-tumor activity in patients with melanoma who had failed prior anti-PD1 therapy. This data was presented at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona.

The IGNYTE clinical trial, which included 140 patients, showed that RP1 plus nivolumab resulted in responses in both injected and non-injected tumors, including visceral lesions. Importantly, the treatment was well-tolerated, with most adverse events being mild to moderate.

“These positive data are a significant step forward for patients with melanoma who have limited treatment options,” said Kostas Xynos, MD, PhD, MBA, Chief Medical Officer of Replimune. “The data from IGNYTE forms the basis for our upcoming Biologics License Application (BLA) submission for RP1 in anti-PD1 failed melanoma, which we expect to submit in the second half of 2024.”

RP1 is an oncolytic immunotherapy based on a genetically modified herpes simplex virus designed to directly kill tumor cells and stimulate a systemic anti-tumor immune response. This unique dual activity makes RP1 a promising treatment option for various cancers.

Replimune is committed to advancing RP1 and other novel oncolytic immunotherapies to provide new and effective treatment options for cancer patients.

**About Replimune Group, Inc.**

Replimune Group, Inc. is a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies. The company’s RPx platform is based on a potent HSV-1 backbone designed to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.

**Disclaimer:** This news article is based on the information provided in the original press release and should not be considered medical advice.

Read More